S.Amdt. 990Senate109th Congress (2005-2007)

To provide for a study relative to medical isotope production.

What it does: Rewrites the text the amendment would insert
Sponsored by Jon KylSen. Jon Kyl (R-AZ)
Submitted June 23, 2005

What it changes

1 change to H.R. 6

Rewrites the amendment
  1. Rewrites the text the amendment would insert

    Rewrites the amendmentIn place of the text the amendment being amended would insert

    Inserted: SEC. 621. MEDICAL ISOTOPE PRODUCTION: NONPROLIFERATION, ANTITERRORISM, AND RESOURCE REVIEW.

    Inserted: (a) Definitions.--In this section:

    Inserted: (1) Highly enriched uranium for medical isotope production.--The term "highly enriched uranium for medical isotope production" means highly enriched uranium contained in, or for use in, targets to be irradiated for the sole purpose of producing medical isotopes.

    Inserted: (2) Medical isotopes.--The term "medical isotopes" means radioactive isotopes, including molybdenum-99, that are used to produce radiopharmaceuticals for diagnostic or therapeutic procedures on patients.

    Inserted: (b) Study.--

    Inserted: (1) In general.--Not later than 60 days after the date of enactment of this Act, the Secretary shall enter into an arrangement with the National Academy of Sciences for the conduct of a study of issues associated with section 134 of the Atomic Energy Act of 1954 (42 U.S.C. 2160d), including issues associated with the implementation of that section.

    Inserted: (2) Contents.--The study shall include an analysis of--

    Inserted: (A) the effectiveness to date of section 134 of the Atomic Energy Act of 1954 (42 U.S.C. 2160d) in facilitating the conversion of foreign reactor fuel and targets to low-enriched uranium, which reduces the risk that highly enriched uranium will be diverted and stolen;

    Inserted: (B) the degree to which isotope producers that rely on United States highly enriched uranium are complying with the intent of section 134 of the Atomic Energy Act of 1954 (42 U.S.C. 2160d) to expeditiously convert targets to low-enriched uranium;

    Inserted: (C) the adequacy of physical protection and material control and accounting measures at foreign facilities that receive United States highly enriched uranium for medical isotope production, in comparison to Nuclear Regulatory Commission regulations and Department administrative requirements;

    Inserted: (D) the likely consequences of an exemption of highly enriched uranium exports for medical isotope production from section 134(a) of the Atomic Energy Act of 1954 (42 U.S.C. 2160d(a)) for--

    Inserted: (i) United States efforts to eliminate highly enriched uranium commerce worldwide through the support of the Reduced Enrichment in Research and Test Reactors program; and

    Show 8 more inserted paragraphs

    Inserted: (ii) other United States nonproliferation and antiterrorism initiatives;

    Inserted: (E) incentives that could supplement the incentives of section 134 of the Atomic Energy Act of 1954 (42 U.S.C. 2160d) to further encourage foreign medical isotope producers to convert from highly enriched uranium to low-enriched uranium;

    Inserted: (F) whether implementation of section 134 of the Atomic Energy Act of 1954 (42 U.S.C. 2160d) has ever caused, or is likely to cause, an interruption in the production and supply of medical isotopes in needed quantities;

    Inserted: (G) whether the United States supply of isotopes is sufficiently diversified to withstand an interruption of production from any 1 supplier, and, if not, what steps should be taken to diversify United States supply; and

    Inserted: (H) any other aspects of implementation of section 134 of of the Atomic Energy Act of 1954 (42 U.S.C. 2160d) that have a bearing on Federal nonproliferation and antiterrorism laws (including regulations) and policies.

    Inserted: (3) Timing; consultation.--The National Academy of Sciences study shall be--

    Inserted: (A) conducted in full consultation with the Secretary of State, the staff of the Reduced Enrichment in Research and Test Reactors program at Argonne National Laboratory, and other interested organizations and individuals with expertise in nuclear nonproliferation; and

    Inserted: (B) submitted to Congress not later than 18 months after the date of enactment of this Act.

    Original wording

    In lieu of the matter proposed to be inserted, insert the following:

Read automatically from the Congressional Record. Check the original before relying on it.

As printed

SA 990. Mr. KYL (for himself, Mr. Lugar, Mr. Lott, and Mr. Schumer) submitted an amendment intended to be proposed by him to the bill H.R. 6, to ensure jobs for our future with secure, affordable, and reliable energy; as follows:

In lieu of the matter proposed to be inserted, insert the following:

SEC. 621. MEDICAL ISOTOPE PRODUCTION: NONPROLIFERATION, ANTITERRORISM, AND RESOURCE REVIEW.

(a) Definitions.--In this section:

(1) Highly enriched uranium for medical isotope production.--The term “highly enriched uranium for medical isotope production” means highly enriched uranium contained in, or for use in, targets to be irradiated for the sole purpose of producing medical isotopes.

(2) Medical isotopes.--The term “medical isotopes” means radioactive isotopes, including molybdenum-99, that are used to produce radiopharmaceuticals for diagnostic or therapeutic procedures on patients.

(b) Study.--

(1) In general.--Not later than 60 days after the date of enactment of this Act, the Secretary shall enter into an arrangement with the National Academy of Sciences for the conduct of a study of issues associated with section 134 of the Atomic Energy Act of 1954 (42 U.S.C. 2160d), including issues associated with the implementation of that section.

(2) Contents.--The study shall include an analysis of--

(A) the effectiveness to date of section 134 of the Atomic Energy Act of 1954 (42 U.S.C. 2160d) in facilitating the conversion of foreign reactor fuel and targets to low-enriched uranium, which reduces the risk that highly enriched uranium will be diverted and stolen;

(B) the degree to which isotope producers that rely on United States highly enriched uranium are complying with the intent of section 134 of the Atomic Energy Act of 1954 (42 U.S.C. 2160d) to expeditiously convert targets to low-enriched uranium;

(C) the adequacy of physical protection and material control and accounting measures at foreign facilities that receive United States highly enriched uranium for medical isotope production, in comparison to Nuclear Regulatory Commission regulations and Department administrative requirements;

(D) the likely consequences of an exemption of highly enriched uranium exports for medical isotope production from section 134(a) of the Atomic Energy Act of 1954 (42 U.S.C. 2160d(a)) for--

(i) United States efforts to eliminate highly enriched uranium commerce worldwide through the support of the Reduced Enrichment in Research and Test Reactors program; and

(ii) other United States nonproliferation and antiterrorism initiatives;

(E) incentives that could supplement the incentives of section 134 of the Atomic Energy Act of 1954 (42 U.S.C. 2160d) to further encourage foreign medical isotope producers to convert from highly enriched uranium to low-enriched uranium;

(F) whether implementation of section 134 of the Atomic Energy Act of 1954 (42 U.S.C. 2160d) has ever caused, or is likely to cause, an interruption in the production and supply of medical isotopes in needed quantities;

(G) whether the United States supply of isotopes is sufficiently diversified to withstand an interruption of production from any 1 supplier, and, if not, what steps should be taken to diversify United States supply; and

(H) any other aspects of implementation of section 134 of of the Atomic Energy Act of 1954 (42 U.S.C. 2160d) that have a bearing on Federal nonproliferation and antiterrorism laws (including regulations) and policies.

(3) Timing; consultation.--The National Academy of Sciences study shall be--

(A) conducted in full consultation with the Secretary of State, the staff of the Reduced Enrichment in Research and Test Reactors program at Argonne National Laboratory, and other interested organizations and individuals with expertise in nuclear nonproliferation; and

(B) submitted to Congress not later than 18 months after the date of enactment of this Act.

Legislative Activity

Stay on top of the latest movement without scrolling through every action

4 earlier actions
Floor Latest Action

Senate amendment submitted

June 23, 2005

View full timeline
Floor

Senate amendment submitted

June 23, 2005

Floor

Senate amendment agreed to: Amendment SA 990 as modified agreed to in Senate by Unanimous Consent.

June 23, 2005

Floor

Senate amendment proposed (on the floor): Amendment SA 990 proposed by Senator Kyl.

June 23, 2005

Floor

Amendment SA 990 proposed by Senator Kyl. (consideration: CR S7249-7251) To provide for a study relative to medical isotope production.

June 23, 2005

Floor

Amendment SA 990 as modified agreed to in Senate by Unanimous Consent. (text as modified: CR S7249-7250)

June 23, 2005